Androgen deprivation therapy is a cornerstone of prostate cancer treatment. Pharmacological androgen deprivation includes gonadotropin-releasing hormone agonism and antagonism, androgen receptor inhibition, and CYP17 (cytochrome P450 17A1) inhibition. Studies in the past decade have raised concerns about the potential for androgen deprivation therapy to increase the risk of adverse cardiovascular events such as myocardial infarction, stroke, and cardiovascular mortality, possibly by exacerbating cardiovascular risk factors. In this review, we summarize existing data on the cardiovascular effects of androgen deprivation therapy. Among the therapies, abiraterone stands out for increasing risk of cardiac events in meta-analyses of both randomized controlled trials and observational studies. We find a divergence between observational studies, which show consistent positive associations between androgen deprivation therapy use and cardiovascular disease, and randomized controlled trials, which do not show these associations reproducibly.

中文翻译：

---

雄激素剥夺疗法对前列腺癌的心血管影响：当代荟萃分析。

雄激素剥夺疗法是前列腺癌治疗的基石。药理学雄激素剥夺包括促性腺激素释放激素激动和拮抗、雄激素受体抑制和 CYP17（细胞色素 P450 17A1）抑制。过去十年的研究引起了人们对雄激素剥夺疗法可能会增加心肌梗死、中风和心血管死亡率等不良心血管事件风险的担忧，这可能会加剧心血管危险因素。在这篇综述中，我们总结了雄激素剥夺疗法对心血管影响的现有数据。在这些疗法中，在随机对照试验和观察性研究的荟萃分析中，阿比特龙因增加心脏事件风险而脱颖而出。我们发现观察性研究之间存在分歧，